CEGE

Here are some of today’s top stories affecting key drug and biotech stocks, accompanied with links through to more detailed information and analysis at BioHealthInvestor.com: New short-interest...
Douglas A. McIntyre
We have run a watch list of companies under their own strategic review, and the number of biotech (or grouped with biotech) stocks under this description is just staggering.   We published a full...
Douglas A. McIntyre
Freddie Mac (FRE) is one sale at $.65. A day-trader’s dream, down from a 52-week high of $65.88.Fannie Mae (FNM) Almost a better deal. Sells off to $.65 from 52-week high of $68.60.Biodel (BIOD)...
Douglas A. McIntyre
Ford (F) Oil moves up. Drops to $4.25 from a 52-week high of $9.24.Nexmed (NEXM) Drug trial problems. Falls to $.23 from a 52-week high of $.1.87.Cell Genesys (CEGE) Drug trial problems. Plunges to...
Douglas A. McIntyre
Cell Genesys CEO Stephen A. Sherwin, M.D made $1.3 million last year, with $577,500 coming from base salary. He did so well, in the eyes of the board, that his base was raised to $602,500. Who knows...
Douglas A. McIntyre
AMAG Pharmaceuticals (NASDAQ: AMAG) has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI) beginning May 19, 2008. AMAG shares up $1.26 at $39.85. The 52-week range is $38.16 to $72.95. Cell...
Douglas A. McIntyre
Cell Genesys, Inc. (NASDAQ: CEGE) plans to offer 7.1 million shares of common stock and warrants at an equivalent of $4.22 per share with a single institutional investor, for an equity offering...
Douglas A. McIntyre
Cell Genesys, Inc. (NASDAQ: CEGE) has announced a global alliance with Takeda Pharmaceutical Company Limited in Japan.  The companies will develop and commercialize Cell Genesys’ GVAX...
Douglas A. McIntyre
Antigenics Inc.  (NASDAQ: AGEN) A study for Cancer vaccine, Oncophage, for the treatment of metastatic melanoma showed mixed results this morning. Shares are down almost 7% to $2.17. The 52 week...
Douglas A. McIntyre
Today was a brutal day for risk stocks, and biotechs are often thought of as risky to stocks as Russian Roulette is to your head.  But Biotechs are also a source of safety IF they are winners,...
Douglas A. McIntyre
Stock Tickers: DNDN, NFLD, NSTK, ADLR, ALTH, COLY, CEGE, NUVO Many of the recent biotech implosions are always interesting to see if short sellers are getting out of the way or adding pressure. ...
Douglas A. McIntyre
Vertex (VRTX-NASDAQ) is seeing quite a bit of trading today ahead of a data presentation tomorrow.  This one may have been very active all on its own, but since Dendreon (DNDN-NASDAQ) made its...
Douglas A. McIntyre
Cell Genesys, Inc. (CEGE-NASDAQ) has done what many small biotechs do that are in need of cash: sell shares in a private placement "PIPE" after a sharp stock run-up.  It has entered...
Douglas A. McIntyre